ES2498190T3 - Receptores de linfocitos T - Google Patents

Receptores de linfocitos T Download PDF

Info

Publication number
ES2498190T3
ES2498190T3 ES10734524.1T ES10734524T ES2498190T3 ES 2498190 T3 ES2498190 T3 ES 2498190T3 ES 10734524 T ES10734524 T ES 10734524T ES 2498190 T3 ES2498190 T3 ES 2498190T3
Authority
ES
Spain
Prior art keywords
amino acid
tcr
seq
chain
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10734524.1T
Other languages
English (en)
Spanish (es)
Inventor
Bent Karsten Jakobsen
Naomi Harwood
Nathaniel Ross Liddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunocore Ltd
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Application granted granted Critical
Publication of ES2498190T3 publication Critical patent/ES2498190T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES10734524.1T 2009-07-03 2010-07-01 Receptores de linfocitos T Active ES2498190T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0911566 2009-07-03
GBGB0911566.8A GB0911566D0 (en) 2009-07-03 2009-07-03 T cell receptors
PCT/GB2010/001277 WO2011001152A1 (en) 2009-07-03 2010-07-01 T cell receptors

Publications (1)

Publication Number Publication Date
ES2498190T3 true ES2498190T3 (es) 2014-09-24

Family

ID=41008692

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10734524.1T Active ES2498190T3 (es) 2009-07-03 2010-07-01 Receptores de linfocitos T

Country Status (19)

Country Link
US (2) US8519100B2 (https=)
EP (1) EP2448963B1 (https=)
JP (2) JP5872464B2 (https=)
CN (3) CN102574906A (https=)
AU (1) AU2010267758C1 (https=)
BR (1) BR112012000107A2 (https=)
CA (1) CA2766505C (https=)
DK (1) DK2448963T3 (https=)
EA (1) EA026918B1 (https=)
ES (1) ES2498190T3 (https=)
FI (1) FIC20220037I1 (https=)
FR (1) FR22C1046I2 (https=)
GB (1) GB0911566D0 (https=)
LU (1) LUC00278I2 (https=)
MX (1) MX2012000155A (https=)
NL (1) NL301193I2 (https=)
PT (1) PT2448963E (https=)
WO (1) WO2011001152A1 (https=)
ZA (1) ZA201109522B (https=)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
EP2760892A1 (en) 2011-09-29 2014-08-06 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
AU2013208364B2 (en) 2012-01-13 2017-10-26 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
ES2719495T5 (en) 2012-05-07 2025-09-10 Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
EP3718556A3 (en) 2012-08-31 2020-12-30 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
EP4088737A3 (en) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
US10377808B2 (en) * 2013-01-29 2019-08-13 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch High avidity antigen recognizing constructs
RU2645256C2 (ru) * 2013-06-26 2018-02-19 Гуандун Сянсюэ Лайф Сайенсис, Лтд. Высокостабильный т-клеточный рецептор и способ его получения и применения
EP3071594A4 (en) * 2013-11-22 2017-05-03 The Board of Trustees of the University of Illionis Engineered high-affinity human t cell receptors
DE202014002754U1 (de) 2014-03-31 2015-07-03 Christian Piotrowski Ausgusssystem mit Pullring der mit der Folie verbunden ist.
CA2945816A1 (en) 2014-04-15 2015-10-22 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
CN106459176B (zh) * 2014-06-18 2018-07-06 广东香雪精准医疗技术有限公司 高亲和力hcv t细胞受体
WO2016014725A1 (en) * 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
CN107074970B (zh) * 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
AU2014407539B2 (en) * 2014-10-02 2020-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
JP7372728B2 (ja) * 2014-10-31 2023-11-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改変ｔ細胞に関する方法および組成物
EP3215164A1 (en) 2014-11-03 2017-09-13 Immures S.r.l. T cell receptors
GB201506642D0 (en) * 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
WO2016193301A1 (en) * 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T-cell receptor specific antibodies
HK1253694A1 (zh) * 2015-06-01 2019-06-28 Medigene Immunotherapies Gmbh T细胞受体文库
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516277D0 (en) * 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
PL3430037T3 (pl) 2016-03-16 2022-12-19 Immatics Biotechnologies Gmbh Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
ES2968802T3 (es) 2016-03-16 2024-05-14 Immatics Biotechnologies Gmbh Células T transfectadas y receptores de células T para su uso en inmunoterapia contra el cáncer
GB201604953D0 (en) 2016-03-23 2016-05-04 Immunocore Ltd T cell receptors
EP3436497B1 (en) 2016-03-28 2022-08-31 Dow Global Technologies LLC Two-component solventless adhesive compositions and methods of making same
WO2017208018A1 (en) * 2016-06-02 2017-12-07 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
DE102016115246C5 (de) 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
HUE057094T2 (hu) 2016-08-17 2022-04-28 Immatics Biotechnologies Gmbh T-sejt receptorok és a velük végzett immunterápia
US11453726B2 (en) * 2016-09-15 2022-09-27 Quadrucept Bio Limited Multimers, tetramers and octamers
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
MX2019010972A (es) 2017-03-15 2019-12-02 Hutchinson Fred Cancer Res Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
AU2018337142B2 (en) * 2017-09-22 2025-07-03 Wuxi Biologics Ireland Limited. Novel bispecific CD3/CD19 polypeptide complexes
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
US20200308279A1 (en) 2017-10-06 2020-10-01 Oslo Universitetssykehus Hf Chimeric antigen receptors
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
US12606816B2 (en) * 2018-07-31 2026-04-21 Janux Therapeutics, Inc. Inhibitory T cell receptor peptides and discovery methods
CN113166778A (zh) * 2018-09-05 2021-07-23 葛兰素史克知识产权开发有限公司 T细胞修饰
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
ES2974424T3 (es) 2019-01-17 2024-06-27 Immunocore Ltd Formulaciones
GB201901306D0 (en) * 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
CN114423499A (zh) * 2019-06-06 2022-04-29 佳努克斯治疗公司 与肿瘤激活的t细胞衔接子相关的组合物和方法
KR20220052944A (ko) * 2019-07-30 2022-04-28 유니버시티 헬스 네트워크 Mhc 클래스 ii 분자 및 이의 사용 방법
CN111234004B (zh) * 2020-02-28 2023-03-28 陕西九州新药评价研究有限公司(西安新药评价研究中心) 识别wt1抗原短肽的t细胞受体及其应用
GB202006629D0 (en) * 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
WO2021236548A1 (en) * 2020-05-18 2021-11-25 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
CN112239495B (zh) * 2020-10-29 2022-04-12 上海药明生物技术有限公司 稳定的tcr结构及应用
CN114853879A (zh) * 2021-02-03 2022-08-05 香雪生命科学技术（广东）有限公司 一种识别hpv的t细胞受体
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
US12103971B2 (en) 2022-02-20 2024-10-01 Immunocore Limited HIV specific binding molecules
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2023246911A1 (zh) * 2022-06-24 2023-12-28 北京可瑞生物科技有限公司 基于t细胞受体的双特异性多肽分子及其用途
WO2024013402A1 (en) 2022-07-15 2024-01-18 Gadeta B.V. Novel soluble gamma t-cell (or soluble delta t-cell) receptor chains (or soluble gammadelta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
MX2025001960A (es) 2022-08-18 2025-05-02 Immunocore Ltd Moléculas de unión multidominio
KR20250051727A (ko) 2022-08-18 2025-04-17 이뮤노코어 리미티드 멀티-도메인 결합 분자
KR20250051722A (ko) 2022-08-18 2025-04-17 이뮤노코어 리미티드 멀티-도메인 결합 분자
CN120225664A (zh) * 2022-09-30 2025-06-27 瑅安生物医药（杭州）有限公司 一种修饰细胞及其用途
EP4634216A1 (en) 2022-12-16 2025-10-22 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
CN121532421A (zh) * 2023-06-21 2026-02-13 北京可瑞生物科技有限公司 经修饰的tcr恒定区及其在tcr融合蛋白中的用途
GB202315181D0 (en) 2023-10-03 2023-11-15 Immunocore Ltd Peptide-HLA binding molecules
WO2025087436A1 (zh) * 2023-10-27 2025-05-01 北京可瑞生物科技有限公司 基于t细胞受体的多特异性多肽分子及其组合物和用途
WO2025094054A1 (en) 2023-11-01 2025-05-08 Immunocore Limited Method for purifying small multi-domain proteins
GB202320012D0 (en) 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
CN118108833B (zh) * 2024-03-12 2025-05-02 缇纱(合肥)生物技术有限公司 引入外源二硫键的tcr恒定区及其产品和应用
WO2025224692A1 (en) 2024-04-25 2025-10-30 Immunocore Limited Method of treating cancer using a gene expression signature
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688747A (en) 1994-08-22 1997-11-18 Becton Dickinson And Company Water based lubricant solution
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
WO1999060120A2 (en) * 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
AU2002321581C1 (en) * 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
DE60327795D1 (de) 2002-11-09 2009-07-09 Immunocore Ltd T zell rezeptor "display"
GB0227351D0 (en) * 2002-11-22 2002-12-31 Isis Innovation Soluble T-cell receptors
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
CN101035561A (zh) * 2004-03-24 2007-09-12 特罗斯药品公司 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
GB0411125D0 (en) * 2004-05-19 2004-06-23 Avidex Ltd Method of improving T-cell receptors
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
US20060045884A1 (en) * 2004-08-26 2006-03-02 Board Of Regents Vaccines for autoimmune and infectious disease
US7915036B2 (en) * 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
JP2008520227A (ja) * 2004-11-18 2008-06-19 メディジーン リミテッド 可溶性二官能性タンパク質
ES2665422T3 (es) * 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
EP1795599A1 (en) * 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
CA2651174A1 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
EP2087000A2 (en) 2006-09-29 2009-08-12 Immunocore Ltd. T cell therapies
AU2008206442B2 (en) 2007-01-12 2012-10-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services gp100-specific T cell receptors and related materials and methods of use
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors

Also Published As

Publication number Publication date
ZA201109522B (en) 2013-05-29
CN107266560A (zh) 2017-10-20
US20120225481A1 (en) 2012-09-06
CN102574906A (zh) 2012-07-11
DK2448963T3 (da) 2014-08-25
JP5872464B2 (ja) 2016-03-01
JP2012531904A (ja) 2012-12-13
EA026918B1 (ru) 2017-05-31
AU2010267758A1 (en) 2012-02-09
CN104017067B (zh) 2017-11-03
GB0911566D0 (en) 2009-08-12
HK1169422A1 (en) 2013-01-25
US9068178B2 (en) 2015-06-30
MX2012000155A (es) 2012-06-28
AU2010267758B2 (en) 2014-09-04
US8519100B2 (en) 2013-08-27
CN104017067A (zh) 2014-09-03
NL301193I2 (nl) 2022-11-24
JP6186412B2 (ja) 2017-08-23
FIC20220037I1 (fi) 2022-08-31
EA201270135A1 (ru) 2012-09-28
FR22C1046I1 (fr) 2022-10-14
EP2448963B1 (en) 2014-06-04
US20140099699A1 (en) 2014-04-10
CA2766505C (en) 2019-01-22
PT2448963E (pt) 2014-09-01
FR22C1046I2 (fr) 2025-04-04
AU2010267758C1 (en) 2015-01-22
WO2011001152A1 (en) 2011-01-06
NL301193I1 (https=) 2022-08-17
CA2766505A1 (en) 2011-01-06
BR112012000107A2 (pt) 2016-11-01
JP2016039812A (ja) 2016-03-24
EP2448963A1 (en) 2012-05-09
LUC00278I2 (https=) 2025-05-12

Similar Documents

Publication Publication Date Title
ES2498190T3 (es) Receptores de linfocitos T
ES2788188T5 (es) Receptores de linfocitos T
ES2891321T3 (es) Receptores de células T
JP7452880B2 (ja) Ｓｓｘ２抗原を識別するｔ細胞受容体
ES2991142T3 (es) Receptores de linfocitos T
ES2914648T3 (es) Receptores de células T
ES2734190T3 (es) Receptores de linfocitos T
JP6751391B2 (ja) Ｔ細胞受容体
US20130149289A1 (en) T cell receptor mutants
KR20160058767A (ko) Ｔ 세포 수용체
CN106478808B (zh) 识别ny-eso-1抗原短肽的t细胞受体
TW202144401A (zh) 一種辨識afp的t細胞受體
TW202140532A (zh) 一種辨識afp的t細胞受體及其編碼序列
WO2023241391A1 (zh) 一种结合ssx2抗原的tcr分子及其应用
HK1169422B (en) T cell receptors